Treatment of Behavioral Symptoms in Alzheimer's Disease

NCT ID: NCT00009217

Last Updated: 2016-05-24

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 44 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 1999-01-31
• Study Completion Date: 2004-12-31

Brief Summary

The optimal strategy for the treatment of behavioral complications in patients with probable Alzheimer's disease (AD) remains unclear.

The objective of this study is to evaluate the risk of relapse following discontinuation of haloperidol in patients with Alzheimer's disease (AD) with psychosis or agitation who respond to it.

In Phase A of this study, AD outpatients with behavioral complications receive 20 weeks of open haloperidol treatment with an oral dose of 1-5 mg daily, titrated individually to achieve the optimal trade-off between efficacy and side effects. Responders to Phase A participate in Phase B, a 24-week continuation trial in which patients are randomized to continuation haloperidol or placebo.

The primary outcome is the time to relapse of psychosis or behavioral disturbance.

Detailed Description

The study involves two phases. Outpatients with AD who meet inclusion/ exclusion criteria enter Phase A, the 20 week open acute treatment phase that uses a flexible dose regimen of haloperidol 1-5 mg daily. Haloperidol is started at an oral dose of 1 mg daily, with subsequent dose titration in 1 mg increments until the optimal dose is reached, i.e., optimal trade-off between efficacy and side effects. At the end of Phase A, patients who do not meet criteria for clinical response exit the protocol and is treated openly with alternative medications.

Phase A responders enter Phase B, a 24-week random assignment, placebo-controlled, continuation trial. Randomization is stratified by the severity of dementia and by the presence of psychosis. Half the patients are randomized to haloperidol (continuing at the same dose as at the end of Phase A), and the other half are randomized to placebo. Patients who relapse during Phase B exit the protocol and receive open treatment.

In Phase A, patients are followed at 0, 2, 4 weeks and every 4 weeks thereafter until 20 weeks. In the discontinuation trial, Phase B, patients are followed at 0, 1, 2, 4, week time points and every 4 weeks thereafter until 24 weeks. If a patient shows signs of relapse, the patient is brought in for more frequent visits, regardless of the stage of the protocol.

Conditions

Alzheimer's Disease; Psychosis; Agitation

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Haloperidol-Haloperidol

Haloperidol for 20 weeks followed by haloperidol for 24 weeks

Group Type: ACTIVE_COMPARATOR

Haloperidol-Haloperidol

Intervention Type: DRUG

Haloperidol open label flexible dose 1-5 mg daily for 20 weeks followed by haloperidol double-blind 1-5 mg for 24 weeks

Haloperidol-Placebo

Haloperidol for 20 weeks followed by placebo for 24 weeks

Group Type: PLACEBO_COMPARATOR

Haloperidol-Placebo

Intervention Type: DRUG

Haloperidol open-label flexible dose of 1-5 mg for 20 weeks followed by placebo double-blind for 24 weeks

Interventions

Haloperidol-Haloperidol

Haloperidol open label flexible dose 1-5 mg daily for 20 weeks followed by haloperidol double-blind 1-5 mg for 24 weeks

Intervention Type: DRUG

Haloperidol-Placebo

Haloperidol open-label flexible dose of 1-5 mg for 20 weeks followed by placebo double-blind for 24 weeks

Intervention Type: DRUG

Other Intervention Names

Haldol; Haldol

Eligibility Criteria

Inclusion Criteria

• Meets DSM-IV criteria for dementia either sex, age 50-95 years
• Meets NINCDS-ADRDA criteria for probable Alzheimer's disease
• Meets Folstein Mini-Mental State Exam score of 5-26, inclusive
• Intellectual impairment reported for at least six months
• Availability of family member who has had direct contact with the patient for an average of at least once every week during the three months prior to study entry
• Has current symptoms of psychosis or agitation. Criteria for "psychosis" requires the presence of delusions and/or hallucinations identified by the Columbia University Scale for Psychopathology in Alzheimer's Disease (CUSPAD) and a minimum Brief Psychiatric Rating Scale (BPRS) psychosis factor score of at least 4 (moderate severity) on one of the following two items: These two items comprise the psychosis factor, excluding the item for conceptual disorganization. Agitation is defined as a score of greater than 3 (present at least 10 days per month) on one or more of the CERAD Behavioral Rating Scale for Dementia items for agitation, purposeless wandering, verbal aggression or physical aggression.
• Free of psychotropic medication for at least two weeks prior to study entry, or able to tolerate medication washout for this period.
• Informed consent by patient and family member, as per IRB procedures at New York State Psychiatric Institute.

Exclusion Criteria

• Acute unstable medical condition, delirium, alcohol or substance abuse or dependence within the past 1 year
• Clinical evidence of stroke, other dementias including vascular or Lewy body or frontotemporal dementia, multiple sclerosis, Parkinson's disease, Huntington's disease, tardive dyskinesia
• Diagnosis of a psychotic disorder antedating the onset of dementia
• Antipsychotic medication usage during 4 weeks prior to study entry
• Contraindication to the use of haloperidol

• Minimum Eligible Age: 50 Years
• Maximum Eligible Age: 95 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Institute of Mental Health (NIMH)

NIH

Sponsor Role: collaborator

New York State Psychiatric Institute

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Davangere Devanand, M.D.

Role: PRINCIPAL_INVESTIGATOR

Columbia University College of Physicians and Surgeon

Locations

New York State Psychiatric Institute

New York, New York, United States

Countries

United States

References

Devanand DP, Pelton GH, Cunqueiro K, Sackeim HA, Marder K. A 6-month, randomized, double-blind, placebo-controlled pilot discontinuation trial following response to haloperidol treatment of psychosis and agitation in Alzheimer's disease. Int J Geriatr Psychiatry. 2011 Sep;26(9):937-43. doi: 10.1002/gps.2630. Epub 2010 Dec 28.

Reference Type: RESULT

PMID: 21845596 (View on PubMed)

Related Links

http://www.ncbi.nlm.nih.gov/pubmed/21845596

link to Pubmed abstract

Other Identifiers

R01MH055735

Identifier Type: NIH

Identifier Source: secondary_id

View Link

#4051R

Identifier Type: -

Identifier Source: org_study_id

NCT00000183

Identifier Type: -

Identifier Source: nct_alias